Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Lexaria Bioscience ( (LEXX) ) is now available.
On September 19, 2025, Lexaria Bioscience Corp. terminated its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, which was initially established on August 21, 2024. This agreement allowed the company to issue and sell up to $5,000,000 in common stock shares. By the termination date, Lexaria had sold 14,995 shares for gross proceeds of $38,236.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Average Trading Volume: 179,365
Technical Sentiment Signal: Sell
Current Market Cap: $27.77M
Learn more about LEXX stock on TipRanks’ Stock Analysis page.